Agaricus bisporus fucogalactan: Structural characterization and pharmacological approaches

作者：Ruthes Andrea C; Rattmann Yanna D; Malquevicz Paiva Simone M; Carbonero Elaine R; Cordova Marina M; Baggio Cristiane H; Santos Adair R S; Gorin Philip A J; Iacomini Marcello^*

来源：Carbohydrate Polymers, 2013, 92(1): 184-191.

DOI：10.1016/j.carbpol.2012.08.071

• Edible mushroom
• Agaricus bisporus
• Fucogalactan
• Sepsis
• Anti-inflammatory
• Pain

The fucogalactan from Agaricus bisporus (EFP-Ab) obtained on aqueous extraction followed by purification had M-w 37.1 x 10(4) g mol(-1) relative to a (1 -> 6)-linked alpha-D-Galp main-chain partially methylated at HO-3, and partially substituted at O-2 by nonreducing end-units of alpha-L-Fucp or beta-D-Galp. EFP-Ab also inhibited significantly the neurogenic and inflammatory phases of formalin-induced licking, however, the antinociceptive effect was more pronounced against the inflammatory phase with ID50 of 36.0 (25.8-50.3) mg kg(-1). In addition, EFP-Ab decreased the lethality induced by CLP. Its administration reduced the late mortality rate by 40%, prevented neutrophil accumulation in lungs and markedly decreased iNOS and COX-2 protein expression by ileum cells. These data show for the first time that EFP-Ab has significant anti-sepsis, antinociceptive and anti-inflammatory actions, which seems to be related to the decreased iNOS and COX-2 expression. Collectively, the present results demonstrate that EFP-Ab could constitute an attractive molecule of interest for the development of new drugs.

• 出版日期2013-1-30